Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Sees Large Drop in Short Interest

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) saw a significant decrease in short interest in the month of March. As of March 15th, there was short interest totalling 500 shares, a decrease of 97.1% from the February 28th total of 17,500 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 365,200 shares, the short-interest ratio is presently 0.0 days.

Provectus Biopharmaceuticals Stock Down 8.1 %

PVCT stock traded down $0.01 during trading on Wednesday, reaching $0.09. 24,873 shares of the stock were exchanged, compared to its average volume of 237,861. Provectus Biopharmaceuticals has a twelve month low of $0.04 and a twelve month high of $0.21. The stock has a 50 day simple moving average of $0.11 and a 200-day simple moving average of $0.11.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.